This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Kumamoto University. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Keishi Miyata: Innovator in Heart Failure Treatment
Introduction
Keishi Miyata is a prominent inventor based in Kumamoto, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment and prevention of heart failure. His innovative approach combines advanced genetic techniques with therapeutic applications.
Latest Patents
Miyata holds a patent for a method aimed at treating or preventing heart failure. The patent describes a pharmaceutical composition that includes a DNA sequence encoding RNA derived from angiopoietin-like protein 2 (ANGPTL2) mRNA. This composition can be utilized alongside siRNA and a vector expressing said siRNA, providing a novel approach to combat heart failure. The patent emphasizes the importance of a pharmaceutically acceptable carrier in delivering the treatment effectively.
Career Highlights
Miyata is affiliated with Kumamoto University, where he conducts research and develops innovative solutions in the medical field. His work has garnered attention for its potential to improve patient outcomes in heart failure management. With 1 patent to his name, he continues to push the boundaries of medical science.
Collaborations
Miyata collaborates with esteemed colleagues such as Haruki Horiguchi and Yuichi Oike. Their combined expertise enhances the research efforts at Kumamoto University, fostering an environment of innovation and discovery.
Conclusion
Keishi Miyata's contributions to heart failure treatment exemplify the impact of innovative thinking in medicine. His work not only advances scientific knowledge but also holds promise for improving the lives of patients suffering from heart conditions.